statement 1 CRISPR-Mb3Cas12a can target a broader range of sequences in murine zygotes 2 compared to AsCas12a and LbCas12a, and has lower on-target effects than Cas9 and 3 high overall knock-in efficiency. 4 5 Abstract 6
Introduction 1
The rapid advancement of CRISPR-Cas-based genome editing technologies has made 2 gene therapy increasingly promising. However, several obstacles remain, including 3 safety concerns due to both off-target and on-target mutations (Adikusuma et al., 2018; 4 Fu et al., 2013; Hsu et al., 2013; Kosicki et al., 2018; Lee and Kim, 2018) and the 5 requirement of proper PAM sequences for efficient and precise cleavage by the 6 commonly used endonucleases (Komor et al., 2017) , e.g., Cas9 and Cas12a/Cpf1. The 7
Cas12a endonuclease has several advantages over Cas9. First, the most commonly 8 used SpCas9 requires NGG PAM sequence, whereas the other widely used AsCas12a 9
and LbCas12a utilize TTTV PAM sequences for efficient genome editing (Cong et al., 10 2013; Jinek et al., 2012; Wang et al., 2013; Zetsche et al., 2015) . Second, Cas12a is 11 guided by a single short CRISPR RNA (crRNA) and can efficiently process its own 12 crRNAs, while Cas9 is directed by dual RNAs consisting of a crRNA and a tracrRNA, 13 and rarely processes its own crRNAs (Cong et al., 2013; Fonfara et al., 2016; Jinek et 14 al., 2012; Zetsche et al., 2017a) . Third, Cas12a has much reduced off-target effects 15 compared to SpCas9 due to its irreversible binding to the target region and strong 16 discrimination against the off-target sequences (Kim et al., 2017; Kleinstiver et al., 2016; 17 Strohkendl et al., 2018) . Finally, Cas9 has been shown to cause on-target mutations 18
including large deletions and insertions (Adikusuma et al., 2018; Kosicki et al., 2018; 19 Lee and Kim, 2018), whereas Cas12a only generates staggered DNA overhangs, which 20 may lead to much lower rate of on-target mutations due to the so-called preferred 21 microhomology-mediated end joining (MMEJ) repair mechanism (Zetsche et al., 2015) . 22
However, practical applications of Cas12a have been severely hindered due, at least in 23 part, to its strict requirement for the TTTV PAM sequence. Although the PAM sequence 24 for FnCas12a has been shown to be YTV (Y stands for C/T and V for A/C/G), the actual 25 editing efficiency of YTV PAM sequences in mammalian cells remains rather low (Tu et 26 al., 2017; Zetsche et al., 2015) . Inspired by a recent report suggesting that Mb3Cas12a 27 edits HEK293 cells at a much higher efficiency through TTV PAM sequences compared 28
to AsCas12a and LbCas12a (Zetsche et al., 2017b preprint) , we explored whether 29
Mb3Cas12a could be utilized for efficient genome editing and production of 30 knockout/knock-in mice lines. 31
Results and Discussion 2
To determine whether Mb3Cas12a is active in mouse zygotes, we first used one crRNA 3 harboring 20nt direct repeats with 20nt spacer recognizing the TTTV PAM sequence of 4
Prps1l1 (Table 1 , Supplementary Fig. 1A, D) , a testis-specific gene dispensable for 5 spermatogenesis (Wang et al., 2018) . One out of six founders obtained has an indel 6 (insertion or deletion) (16.7%) ( Table 1 , Supplementary Fig. 1A, D ), suggesting that 7
Mb3Cas12a indeed works in mouse zygotes. Since AsCas12a and LbCas12a have the 8 ability to process their own crRNAs (Fonfara et al., 2016; Zetsche et al., 2017a ), we 9 next tested whether Mb3Cas12a could do the same. We designed one crRNA 10 harboring two 20nt spacers recognizing two TTTV PAM sequences at Saraf locus 11 (Table 1 , Supplementary Fig. 1B , E). The 20nt spacers were separated by 20nt direct 12 repeats. One out of three founders was edited by spacer 1 (33.3%) ( Table 1 , 13 Supplementary Fig. 1B, E ), suggesting that Mb3Cas12a can indeed process its own 14 crRNAs to edit a specific locus in mouse zygotes. We then determined whether 15
Mb3Cas12a could utilize the TTV PAM sequence in mouse zygotes. We designed one 16 crRNA harboring two 20nt spacers recognizing two TTV PAM sequences of the same 17
Saraf locus (Table 1, Supplementary Fig. 1B , E). One out of four founders was edited 18 with the spacer 2 (25%) ( Supplementary Fig. 1C , F), suggesting that Mb3Cas12a prefers the spacer 27 targeting the TTTV PAM sequence. 28
As the length of crRNAs has been shown to affect the efficiency of Cas12a-29 mediated genome editing (Tu et al., 2017; Zetsche et al., 2015) , we further tested 30 whether the editing efficiency can be improved by optimizing the crRNA structure. We 31 10 higher targeting efficiency (77%, n=20) than the pronuclear and cytoplasmic injection 11 (28.6%, n=39) ( Table 1, Fig. 1C, D) . Therefore, we used 23nt spacer and cytoplasmic 12 microinjection to generate the following indels in mice ( Fig. 2A) . 13
To explore whether Mb3Cas12a could target multiple loci simultaneously, we 14 used one crRNA harboring three 23nt spacers recognizing TTTV PAM sequencing 15 targeting the Prps family, i.e. Prps1, Prps2 and Prps1l1. Eleven founders obtained 16 (100%) were edited by both the Prps1 and Prps1l1 crRNAs, whereas one (9.1%) was 17 edited only by the Prps2 crRNA (Table 1 , Supplementary Fig. 2A ), which may reflect a 18 lower targeting efficiency of this particular crRNA. Next, we used a crRNA containing 19 three 23nt spacers separated by 20nt direct repeats to target miR-10b (Table 1 , 20 Supplementary Fig. 2B , C). Two of the spacers (spacers 2 and 3) were designed to 21 recognize a TTTV PAM sequence, whereas the other one targets a TTV PAM sequence 22 (spacer 1) at miR-10b locus. All the five founders were edited by the two spacers 23 targeting the TTTV PAM sequence (100%), and one of them was edited by the one 24 recognizing the TTV PAM sequence (20%) ( Table 1 , Supplementary Fig. 2B , C). Similar 25 results were also obtained when we used one crRNA containing one 23nt spacer 26 targeting miR-547 with a TTTV PAM sequence and two 23nt spacers targeting miR-509 27 with one TTTV PAM and one TTV PAM. All six founders were edited by the two 28 spacers targeting the TTTV PAM sequence (100%), and one of them was edited by the 29 one recognizing the TTV PAM sequence (16.7%) (Table 1, Fig. 2B , C). Moreover, 30 although the 23nt spacers recognizing TTTV PAM sequence often led to bi-or multi-31 allelic targeting and TTV PAM sequence tended to yield mono-allelic targeting, the 20nt 1 spacers appeared to cause mostly mono-allelic mutations ( Table 1, Fig. 1D , 2C and 2 Supplementary Fig. 1 , 2). Recent reports have shown that Cas9 with one single gRNA 3 tends to induce large indels in genomic DNA in mouse embryonic stem (ES) cells, 4 progenitor cells and zygotes (Adikusuma et al., 2018; Kosicki et al., 2018) , whereas 5
Cas9 with two gRNAs causes large deletions within the two flanking gRNA-targeting 6 sites (Wang et al., 2018) . The incidences of large deletions induced by Cas9 with one 7 single gRNA were 35.7%, 36.5%, and 45% in mouse ES cells, progenitor cells, and 8 zygotes, respectively, whereas the incidence of large insertions was 26.3% in mouse 9 ES cells (Adikusuma et al., 2018; Kosicki et al., 2018) . Interestingly, unlike Cas9, 10
Mb3Cpf-based genome editing predominantly generates indels, containing 11 microhomology (MH) sequences flanking the cleavage sites with one or more spacers 12 within a single crRNA. Among all 42 pups derived from Mb3Cas12a-based editing, only 13 3 contained large insertions (7.1%) induced by 3 spacers in the crRNA, whereas the 14 rest displayed different alleles with either two or more small mutations or one mutant 15 plus one wild-type alleles ( Table 1 , Fig. 1D, 2C and Supplementary Fig. 1, 2 ). Based on 16
RepeatMasker, two large insertions correspond to ERVL (endogenous retroviruses 17 type-L) and ERVL-MaLR (mammalian apparent LTR retrotransposon), respectively, 18 similar phenomenon has been observed in SpCas9 induced double strand breaks 19 (DSBs) (Ono et al., 2015) , suggesting these retrotransposons may hijack the DSBs 20 induced by SpCas9 or Mb3Cas12a. None of the Mb3Cas12a-edited alleles contained 21 large deletions, whereas they are commonly seen in Cas9-editted genes. These results 22 suggest that MMEJ repair mechanism is preferentially adopted in fixing the staggered 23 DNA ends, which may account for the minimal on-target effects in Mb3Cas12a-based 24 genome editing. 25
Given that two-cell homologous recombination (2C-HR)-CRISPR, in which Cas9 26 was tethered with monomeric streptavidin (mSA) that could bind to biotinylated DNA 27 donor template, showed a higher knock-in (KI) efficiency (Gu et al., 2018) , we tested 28 whether Mb3Cas12a-mSA could do the same in generating KI mice (Fig. 3A, B ). We 29 microinjected 2-cell embryos with Mb3Cas12a-mSA mRNA, crRNA targeting Slit2 locus, 30 and biotinylated DNA donor template containing a BamHI restriction enzyme cutting site 31 ( Fig. 3A ). Among 5 founders, 2 (40%) have the knock-in alleles, indicating the 1 Mb3Cas12a-mSA indeed can generate KI mice efficiently ( Fig. 3B, 3C ). During 2 preparation of our manuscript, one study reporting that HkCas12a can target YTV and 3 TYYN PAM sequences in human cell lines was published (Teng et al., 2019) . However, 4 it remains unknown whether HkCas12a works in murine zygotes and what its efficiency 5 is. In summary, our data demonstrate that Mb3Cas12a can edit the murine genome 6 independent of TTTV PAM sequence and with minimal on-target mutations and very 7 high targeting efficiency. Mb3Cas12a-mediated genome editing expands the toolkit for 8 efficient production of mutant mouse lines. 
Plasmids construction 15
To prepare pcDNA3.1-Mb3Cas12a-mSA plasmid, monomeric streptavidin (mSA) DNA 16 fragments amplified from PCS2+Cas9-mSA plasmid (Cat. 103882, Addgene, 17
Watertown, MA) were inserted into the pY117 plasmid (pcDNA3.1-huMb3Cpf1) (Cat. 18 92293, Addgene) via BamHI (Cat. R0136S, NEB, Ipswich, MA) and EcoRI (Cat. 19
R3101S, NEB) restriction sites. 20
For the pUC-Slit2-BamHI plasmid, two homology arms (~1kb) flanking the 21 crRNAs cutting sites of Slit2 locus and pUC empty vector were amplified by Q5® Hot 22
Start High-Fidelity 2X Master Mix (Cat. M0494S, NEB) from mouse tail genomic DNA 23 and pX330 plasmid (Cat. 42230, Addgene), respectively. After purification with Ampure 24 beads, these three DNA fragments were assembled with NEBuilder® HiFi DNA 25
Assembly Master Mix (Cat. E2621L, NEB). BamHI restriction site was introduced 26 between the two homology arms during the PCR amplification. The primers used for 27 plasmids construction are listed in Supplemental Table S1 . 28
Generation of Mb3Cas12a and Mb3Cas12a-mSA mRNA, crRNAs, and donor DNA 30 template 31
To synthesize Mb3Cas12a and Mb3Cas12a-mSA mRNAs, the pY117 plasmid 1 (pcDNA3.1-huMb3Cpf1) (Cat. 92293, Addgene) and pcDNA3.1-Mb3Cas12a-mSA were 2 digested with EcoR I (Cat. R3101S, NEB) overnight at 37°C, followed by purification 3
with Ampure beads and mRNA synthesis with the HiScribe™ T7 ARCA mRNA Kit (Cat. 4 E2065S, NEB). Then the in vitro transcribed mRNAs were treated with DNase I (NEB, 5
Cat. M0303S) to remove the plasmid DNA template, followed by poly(A) tailing using E. 6 coli poly(A) polymerase (Cat. M0276S, NEB). The poly(A)-tailed Mb3Cas12a mRNAs 7 were purified using the RNA Clean & Concentrator™-5 (Cat. R1016, Zymo Research, 8
Irvine, CA) and eluted in a Tris-EDTA solution (Cat.11-01-02-02, IDT, Coralville, IA). 9 crRNAs were designed using Benchling (https://benchling.com/). DNA oligos for 10 making each crRNA were synthesized in the IDT Inc. and listed in Supplemental Table  11 S1. To prepare crRNAs for microinjection, the T7 first strand primer and antisense 12 oligos specific for each crRNA were mixed in 1X T4 DNA ligase buffer and heated to 13 95°C for 5 minutes, and then allowed to cool down to room temperature on the bench. 14 The annealed oligos were used as the templates for in vitro transcription (IVT) using the 15 HiScribe™ T7 High Yield RNA Synthesis Kit (Cat. E2040S, NEB). After IVT, crRNAs 16
were purified using the RNA Clean & Concentrator™-5 (Cat. R1016, Zymo Research) 17 and eluted in Tris-EDTA solution (Cat.11-01-02-02, IDT). 18
To prepare crRNAs for transfection of HEK293 cells, PCR products 19 corresponding to each crRNA were amplified with U6 forward primer and corresponding 20 antisense oligos (as listed in Supplemental Table S1 ) from the pX330 plasmid (Cat. 21 42230, Addgene). After digestion with DpnI (Cat. R0176S, NEB), the PCR products 22
were purified using Ampure beads. 23
The biotinylated donor DNA template was amplified from the pUC-Slit2-BamHI 24 plasmid with biotinylated primers (as listed in Supplemental Table S1 ), followed by 25
DpnI digestion to remove the plasmid and purification with Ampure beads. The animal protocol for this study was approved by the Institutional Animal Care and 5
Use Committee (IACUC) of the University of Nevada, Reno (protocol number 00494). 6
All mice were housed and maintained under specific pathogen free conditions with a 7 temperature-and humidity-controlled animal facility in the Department of Lab Animal 8
Medicine, University of Nevada, Reno. Generation of KO and KI mice were performed 9 as previously described with modifications (Gu et al., 2018; Wang et al., 2018; Wang et 10 al., 2019) . Briefly, 4-6 weeks of FVB/NJ or C57BL/6J female mice were super-ovulated 11 and mated with C57BL/6J stud males; zygotes and 2-cell stage embryos were collected 12 from the oviducts for KO and KI, respectively. For KO, Mb3Cas12a mRNA (200ng/μl) 13 and crRNA (100 ng/μl) were mixed and injected into the cytoplasm or pronucleus of the 14 zygotes in M2 medium (Cat. MR-051-F, Millipore, Burlington, MA). For KI, Mb3Cas12a-15 mSA mRNA (75ng/μl), crRNA (50 ng/μl) and biotinylated donor DNA template (20ng/μl) 16
were mixed and injected into the cytoplasm or pronucleus of the 2-cell embryos in M2 17 medium. After injection, all embryos were cultured for 1h in KSOM+AA medium (Cat. 18 MR-121-D, Millipore) at 37°C under 5% CO 2 in air before being transferred into 7-10 19
week-old female CD1 recipients. 20
Mouse genotyping, T7EI and Sanger sequencing 22
Mouse genotyping was performed as previously described (Wang et al., 2018; Wang et 23 al., 2019) . Briefly, mouse tail or ear snips were lysed in a lysis buffer (40mM NaOH, 24 0.2mM EDTA) for 1h at 95°C, followed by neutralization using the same volume of 25 neutralizing buffer (40mM Tris-HCl). PCR reactions were conducted using Platinum™ 26 SuperFi™ Green PCR Master Mix (Cat. 12359010, Thermo Fisher Scientific). T7EI 27 (Cat. M0302L, NEB) assay was followed to detect the mutations. The positive samples 28 were proceeded with A tailing using GoTaq® Green Master Mix (Cat. M7123, Promega, 29
Madison, WI) for 5min at 95 °C, followed by 15min at 72 °C. The A-tailed PCR products 30
were then ligated to pGEM®-T Easy Vector using pGEM®-T Easy Vector Systems (Cat. 31 1 analyzed using Geneious software. The primers used for genotyping are listed in 2 Supplemental Table S1 Figure 1 A B
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